Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection

Journal of Infectious Diseases

Volumn 200, Issue 11, 2009, Pages 1774-1780

  Zeremski, Marija ^a   Dimova, Rositsa ^b   Brown, Queenie ^a   Jacobson, Ira M ^a   Markatou, Marianthi ^b   Talal, Andrew H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECEPTORS, CXCR3; ROC CURVE;

EID: 72849128563     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/646614     Document Type: Article

References (31)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567 (Pubitemid 41196755) (Pubitemid 41196755)
2. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24:3-8.
3. Davis GL, Keeffe EB, Balart LA. Advances in liver disease: highlights from the 56th Annual Meeting of the American Association for the Study of Liver Disease. Rev Gastroenterol Disord 2006; 6:48-61.
4. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97-104.
5. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34:730-739 (Pubitemid 32488789) (Pubitemid 32488789)
6. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32:904-909 (Pubitemid 32911311) (Pubitemid 32911311)
7. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-1340 (Pubitemid 26181213) (Pubitemid 26181213)
8. Lagging LM, Westin J, Svensson E, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002; 22:136-144 (Pubitemid 34591255) (Pubitemid 34591255)
9. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-2250
10. Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48:1440-1450
11. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14:675-687 (Pubitemid 47414927) (Pubitemid 47414927)
12. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374
13. McCullagh P, Nelder JA. Generalized linear models. London: Chapman and Hall, 1994.
14. The R Project for Statistical Computing. Available at: http://www.r-project.org. Accessed 29 September 2009.
15. Su JQ, Liu JS. Linear combinations of multiple diagnostic markers. J Amer Stat Assoc 1993; 88:1350-1355
16. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526
17. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004; 39:1220-1229 (Pubitemid 38569043) (Pubitemid 38569043)
18. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163:6236-6243
19. Apolinario A, Majano PL, Alvarez-Pérez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97:2861-2870 (Pubitemid 35265441) (Pubitemid 35265441)
20. Apolinario A, Diago M, Lo Iacono O, et al. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. Aliment Pharmacol Ther 2004; 19:551-562 (Pubitemid 38387182) (Pubitemid 38387182)
21. Narumi S, Tominaga Y, Tamaru M, et al. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 158:5536-5544 (Pubitemid 127681264)
22. Nishioji K, Okanoue T, Itoh Y, et al. Increase of chemokine interferoninducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123:271-279 (Pubitemid 32174779) (Pubitemid 32174779)
23. Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005; 106:1175-1182 (Pubitemid 41129575) (Pubitemid 41129575)
24. Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74:360-369 (Pubitemid 38040396) (Pubitemid 38040396)
25. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867-1873 (Pubitemid 41368177) (Pubitemid 41368177)
26. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42:1373-1381 (Pubitemid 43260040) (Pubitemid 43260040)
27. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992
28. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3:8. (Pubitemid 40230475) (Pubitemid 40230475)
29. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-to-advancedliver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41:935-942 (Pubitemid 39575660) (Pubitemid 39575660)
30. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075 (Pubitemid 32322537) (Pubitemid 32322537)
31. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46:775-782 (Pubitemid 46529041) (Pubitemid 46529041)